Sweeny, David J <br/><br/>
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.  [electronic resource] 

 -  Drug metabolism and disposition: the biological fate of chemicals  Jul 2010 
 - 1166-76 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1521-009X 
<br/><br/><label>Standard No.: </label>10.1124/dmd.110.032151  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aminopyridines<br/>Bacteria, Anaerobic--metabolism<br/>Biotransformation<br/>Gastrointestinal Tract--metabolism<br/>Humans<br/>In Vitro Techniques<br/>Inactivation, Metabolic<br/>Liver--metabolism<br/>Male<br/>Microsomes--metabolism<br/>Morpholines<br/>Oxazines--pharmacokinetics<br/>Prodrugs--pharmacokinetics<br/>Pyridines--pharmacokinetics<br/>Pyrimidines